Skip to content

Clinical efficacy and safety of CollaDerm in the management of diabetic foot ulcers: randomized controlled trial

Clinical efficacy and safety of CollaDerm in the management of diabetic foot ulcers

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003802
Enrollment
38
Registered
2019-04-17
Start date
2011-11-29
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : 1) Study group: CollaDerm(collagen dressing) and foam dressing As a general rule, treat the CollaDerm once every 2 to 3 days for 8 weeks in the ulcer area. The size and condition of

Sponsors

Yonsei University Health System, Severance Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) patients with type 1 or type 2 diabetes over 20 years of age 2) Wagner classification of grade 1 and 2 patients with lower limb ulcer 3) Ulcer size = 1 ? 4) Patients who had diabetic foot ulcer for more than 6 weeks 5) If there is any of the following three conditions in the leg with a target foot ulcer at the previous treatment day (V1) ? One or more of the foot arterial sounds of the ankle joint region through Doppler examination ? Percutaneous oxygen partial pressure greater than 30 mmHg ? When pulse is palpable 6) Patients who were negative for microbiological culture after appropriate antibiotic treatment even without systemic or local infection or with infection 7) Subjects who have received sufficient explanations for this clinical trial and then signed the agreement

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women and women of childbearing age who refuse a contraception during the study 2) Patients with sepsis, osteomyelitis, abscess, gangrene or soft tissue infection treated unsuccessfully with debridement 3) Patients diagnosed as venous insufficiency, diabetic fatty necrosis and ulcer with deep vein thrombosis 4) Patients had connective tissue disorder that interferes with wound healing, such as rheumatoid arthritis, systemic lupus erythematosus 5) Patients diagnosed as Charcot–Marie–Tooth disease or sickle cell disesase 6) Patients with chronic wasting disease who are not currently being treated 7) Patients had poor prognosis diseases including malignant tumors 8) Patients had corticosteroids, immunosuppressants, radiation therapy or chemotherapy 9) Patients with hypersensitivity to the constituents of the substance or storage solution used in the manufacturing process 10) Patients known hypersensitivity to bovine-derived components 11) Patients had mental disorder, drugs or alcohol addiction and could not understand the present study 12) Patients whose life is short 13) If the use of a prohibited drug is anticipated during the trial period 14) If patients are taking medicines for other clinical trials within 30 days of participating in this clinical trial 15) Patients not suitable for research based on the researcher’s decision

Design outcomes

Primary

MeasureTime frame
Complete healing rates;Adverse reactions and laboratory tests, signs of vitality

Secondary

MeasureTime frame
Size of ulcer;Depth of ulcer

Countries

Korea, Republic of

Contacts

Public ContactJinwoo Lee

Yonsei University Health System, Severance Hospital

ljwos@yuhs.ac+82-2-2228-2190

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026